Press "esc" to clear
Go to Advanced Search

Showing results

110 of 201
Embargo will expire:
28-Feb-2018 5:00 PM EST
Released to reporters:
23-Feb-2018 1:05 PM EST

EMBARGOED

A reporter's PressPass is required to access this story until the embargo expires on 28-Feb-2018 5:00 PM EST

Channels:

All Journal News, Healthcare, Guns and Violence, NEJM, Local - Massachusetts, Local - Boston Metro

Article ID: 689970

Updated Data Confirms a Durable 75 Percent Overall Response Rate, by Blinded Independent Review, of Larotrectinib in Adults and Children with Tumors Harboring TRK Fusions

Memorial Sloan Kettering Cancer Center

Larotrectinib, a highly selective TRK kinase inhibitor, shows rapid, potent, and durable efficacy in both adult and pediatric patients with solid tumors that harbor TRK fusions, regardless of tumor type or patient age, according to results from three clinical trials published in the New England Journal of Medicine. The landmark data support the foundation of precision oncology by creating a treatment option for a genetically defined cancer while continuing to validate the concept that comprehensive molecular profiling should be strongly considered in people of all ages with advanced solid tumors.

Released:
22-Feb-2018 10:05 AM EST
EXPERT AVAILABLE
Add to Favorites
Comment

Channels:

All Journal News, Cancer, Cell Biology, Children's Health, NEJM, Local - New York, Local - New York Metro

  • Embargo expired:
    21-Feb-2018 5:00 PM EST

Article ID: 689843

Precision Cancer Therapy Effective in Both Children and Adults

Childrens Hospital Los Angeles

Three quarters of patients with a variety of advanced cancers occurring in different sites of the body responded to larotrectinib, a novel therapy that targets a specific genetic mutation. The oral treatment is based on the genetic traits of the tumor and not the organ where the cancer originated.

Released:
20-Feb-2018 12:05 PM EST
EXPERT AVAILABLE
Add to Favorites
Comment

Channels:

All Journal News, Cancer, Children's Health, NEJM, Local - California, Local - LA Metro

car-t-graphic.jpg

Article ID: 688837

Simmons Cancer Center Researchers Part of Historic CAR-T Breakthrough

UT Southwestern Medical Center

A historic study involving researchers from UT Southwestern’s Harold C. Simmons Comprehensive Cancer Center demonstrates the effectiveness of CAR-T therapy, which uses genetically modified immune cells to treat acute lymphoblastic leukemia in children and young adults.

Released:
1-Feb-2018 3:05 PM EST
EXPERT AVAILABLE
Add to Favorites
Comment

Channels:

Cancer, Cell Biology, Genetics, NEJM, Local - Texas, Local - Dallas Metro, All Journal News

UUHC_170824_5006.jpg
  • Embargo expired:
    31-Jan-2018 5:00 PM EST

Article ID: 688502

Catheter Ablation Better Than Pharmacological Atrial Fibrillation Therapies

University of Utah Health

A new study revealed patients receiving radiofrequency catheter ablation compared to traditional drug therapies for atrial fibrillation (AF), a contributing factor to heart failure, had significantly lower hospitalization and mortality rates. The findings are published in the February 1 issue of the New England Journal of Medicine.

Released:
26-Jan-2018 10:00 AM EST
EXPERT AVAILABLE
Add to Favorites

Channels:

All Journal News, Cardiovascular Health, Heart Disease, NEJM

Maude_S_Dr_5x7_488.jpg
  • Embargo expired:
    31-Jan-2018 5:00 PM EST

Article ID: 688535

T Cell Therapy Shows Persistent Benefits in Young Leukemia Patients

Children's Hospital of Philadelphia

Updated results from a global clinical trial of the CAR T-cell therapy, tisagenlecleucel, a landmark personalized treatment for a high-risk form of acute lymphoblastic leukemia (ALL), reveal that children and young adults continued to show high rates of durable, complete remission of their disease. Most side effects were short-lived and reversible.

Released:
26-Jan-2018 12:20 PM EST
EXPERT AVAILABLE
Add to Favorites
Comment

Channels:

All Journal News, Blood Disorders, Cancer, Cell Biology, Children's Health, NEJM, Local - Pennsylvania

  • Embargo expired:
    31-Jan-2018 5:00 PM EST

Article ID: 688711

Landmark International Study: CAR T-Cell Therapy Safe and Effective in Children and Young Adults with Leukemia

Childrens Hospital Los Angeles

Results of the global, multicenter, pivotal phase 2 study that led to the first FDA approval of a gene therapy/cell therapy approach known as CAR T-cell therapy, were published today in the New England Journal of Medicine.

Released:
30-Jan-2018 8:05 PM EST
EXPERT AVAILABLE
Add to Favorites
Comment

Channels:

All Journal News, Blood Disorders, Cancer, Children's Health, NEJM, Local - California, Local - LA Metro, Genetics

IVDrip800.jpg

Article ID: 688461

Drug Discount Program Aimed at Improving Care for Low-Income Patients Generated Gains for Hospitals Without Clear Benefits for the Needy

Harvard Medical School

A 25-year-old drug discount program aimed at boosting resources for hospitals treating low-income patients did not deliver on its promise to enhance care for the needy, according to research from Harvard Medical School and the NYU School of Medicine.

Released:
24-Jan-2018 6:05 PM EST
EXPERT AVAILABLE
Add to Favorites
Comment

Channels:

All Journal News, Healthcare, Patient Safety, Pharmaceuticals, NEJM, Local - Massachusetts, Local - Boston Metro

PETscan.png
  • Embargo expired:
    24-Jan-2018 5:00 PM EST

Article ID: 688456

Alzheimer's Drug Targeting Soluble Amyloid Falls Short in a Large Clinical Trial

Columbia University Medical Center

A paper published today in the New England Journal of Medicine reports that solanezumab, a monoclonal antibody-based treatment for Alzheimer’s disease developed by Eli Lilly that targets amyloid plaques, did not significantly slow cognitive decline.

Released:
24-Jan-2018 4:55 PM EST
EXPERT AVAILABLE
Add to Favorites
Comment

Channels:

Alzheimer's and Dementia, Neuro, NEJM, Local - New York, Local - New York Metro, All Journal News

e-cig-feature.jpg

Article ID: 688285

E-Cigarettes: Harm Reduction or ‘Gateway’ to New Smokers?

Texas A&M University

Smoking is an issue that has been at the heart of public health concerns for decades, with many efforts to restrict tobacco sales, tax cigarettes and sometimes hard-hitting campaigns to get people to quit smoking. But if the tobacco control community has long agreed on the harms of smoking, the place of reducing, rather than eliminating, harm has been hotly contested.

Released:
22-Jan-2018 3:50 PM EST
EXPERT AVAILABLE
Add to Favorites
Comment

Law and Public Policy

Channels:

Public Health, Smoking, NEJM, Local - Texas, All Journal News


Showing results

110 of 201





Chat now!